

FINDING OF NO SIGNIFICANT IMPACT FOR

Marketing Orders for

Marlboro Menthol Special 100s Box, Marlboro Menthol Special Select Box, Marlboro Menthol Special Select Box, Marlboro Menthol Special Select 100s Box, L&M Menthol Box, Marlboro Menthol Green Pack 72's Box, Marlboro Menthol Green Pack 72's Box, L&M Menthol Box, L&M Menthol Box

Manufactured by Philip Morris USA Inc.

The Center for Tobacco Products of the Food and Drug Administration (FDA) has carefully considered the potential environmental impacts of these actions and has concluded that these actions will not have a significant effect on the quality of the human environment. Therefore, environmental impact statements are not required.

Philip Morris USA Inc. wishes to introduce nine combusted, filtered cigarettes into interstate commerce for commercial distribution in the United States and submitted to FDA nine substantial equivalence reports to obtain marketing orders under the provisions of sections 910 and 905(j) of the Federal Food, Drug, and Cosmetic Act.

The Agency prepared the programmatic environmental assessment (PEA), dated February 1, 2019, in accordance with the Council on Environmental Quality's regulations (40 CFR Part 1500) implementing the National Environmental Policy Act (NEPA) and FDA's NEPA regulations (21 CFR 25.40) to support the finding of no significant impact. The evidence supporting this finding is contained in the attached PEA, which is available to the public upon request.

The PEA evaluates potential environmental effects due to manufacturing, use, and disposal of the new products. No increased or new types of environmental impacts due to manufacturing are anticipated. The Agency does not foresee use of the new products would result in new or different environmental impacts. The Agency believes that the disposal of the new products is the same as the disposal conditions of other filtered, combusted cigarettes that are currently marketed in the United States. Therefore, the Agency does not foresee adverse impacts to the environment due to the proposed actions as a result of manufacturing, use and disposal of the new products.

Approved by	Hans M. Rosenfeldt -S	2019.02.01 15:20:07 -05'00'
For	<hr/>	
	Kimberly Benson, Ph.D. Director Division of Nonclinical Science Office of Science Center for Tobacco Products U.S. Food and Drug Administration	